Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Bayer Seeks To Buy Monsanto in $66 Billion Deal

XTALKS VITALS NEWS

Best known for the discovery of aspirin, Bayer’s acquisition of Monsanto would make it the world’s largest seed and crop spray supplier.

Tweetables from this article:

Tweet: Monsanto and Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil http://ctt.ec/ODRnv+Monsanto and Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil.

Share this!

September 21, 2016 | by Sarah Hand, M.Sc.

German pharmaceutical company Bayer has announced its intention to acquire the US-based agribusiness company Monsanto in a $66 billion deal. Best known for the discovery of aspirin, Bayer’s acquisition of Monsanto would make it the world’s largest seed and crop spray supplier.

After four months of negotiations, the companies have agreed upon an all-cash deal valuing Monsanto’s shares at $128 apiece. Hugh Grant, CEO of Monsanto will reportedly earn over $135 million if the sale goes through.

“Today’s announcement is a testament to everything we’ve achieved and the value that we have created for our stakeholders at Monsanto,” said Grant. “We believe that this combination with Bayer represents the most compelling value for our shareowners, with the most certainty through the all-cash consideration.”

Despite mutual agreement between the two companies, the merger will now face the scrutiny of US regulators. Following last year’s merger between Dow Chemical and DuPont, and this year’s deal between ChemChina and Syngenta, the number of global companies in agribusiness is quickly shrinking.



Industry experts are pointing to bumper harvests and declining crop prices as a main driver of consolidation in the agricultural industry. According to farmer’s groups, this reduction in the number of different companies investing in new agricultural technologies could drive up the cost of proprietary seeds and chemical sprays.

If they’re successful, the Bayer-Monsanto merger will be the largest cash only deal on record, as well as the biggest acquisition of an American company by an overseas business. To complete the deal, Bayer will need to secure the approval of regulators in the US, Canada, the EU and Brazil.

“We are entering a new era in agriculture – one with significant challenges that demand new, sustainable solutions and technologies to enable growers to produce more with less,” said Grant. “This combination with Bayer will deliver just that – an innovation engine that pairs Bayer’s crop protection portfolio with our world-class seeds and traits and digital agriculture tools to help growers overcome the obstacles of tomorrow. Together Monsanto and Bayer will build on our proud tradition and respective track records of innovation in the agriculture industry, delivering a more comprehensive and broader set of solutions to growers.”


Keywords: Merger, Agribusiness, Aspirin


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News


Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News


Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


Natural History vs. Registry Studies in Rare Disease


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act


Copyright © 2016-2017 Honeycomb Worldwide Inc.